APA (7th ed.) Citation

M, I., T, K., Y, N., Y, T., Y, H., Y, S., . . . N, S. (2026). Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis. JTO clinical and research reports, 7(4), 100972. https://doi.org/10.1016/j.jtocrr.2026.100972

Chicago Style (17th ed.) Citation

M, Ishihara, et al. "Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis." JTO Clinical and Research Reports 7, no. 4 (2026): 100972. https://doi.org/10.1016/j.jtocrr.2026.100972.

MLA (9th ed.) Citation

M, Ishihara, et al. "Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis." JTO Clinical and Research Reports, vol. 7, no. 4, 2026, p. 100972, https://doi.org/10.1016/j.jtocrr.2026.100972.